Greykasell Wealth Strategies Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greykasell Wealth Strategies Inc. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 708 shares of the biopharmaceutical company's stock, valued at approximately $504,000.

Several other institutional investors have also modified their holdings of the company. Mizuho Securities USA LLC increased its stake in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after purchasing an additional 51,162 shares during the period. Principal Financial Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after buying an additional 2,828 shares in the last quarter. Intact Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $356,000. Simplify Asset Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock valued at $10,082,000 after purchasing an additional 3,231 shares in the last quarter. Finally, Golden State Equity Partners lifted its stake in shares of Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after buying an additional 1,272 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on REGN shares. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Finally, Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $7.40 during midday trading on Wednesday, reaching $672.36. The company's stock had a trading volume of 675,613 shares, compared to its average volume of 626,766. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $73.51 billion, a P/E ratio of 17.56, a PEG ratio of 2.34 and a beta of 0.27. The firm has a 50 day moving average price of $692.84 and a 200-day moving average price of $823.99. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.86 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.